γ-Glutamyltransferase is a promising biomarker for cardiovascular risk

Medical Hypotheses

Volumn 67, Issue 5, 2006, Pages 1060-1064

  Turgut, Okan ^a   Yilmaz, Ahmet ^a   Yalta, Kenan ^a   Karadas, Filiz ^a   Birhan Yilmaz, M ^a  

^a CUMHURIYET UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIC ACID DERIVATIVE; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE; LIPID; XENOBIOTIC AGENT;

ALCOHOL ABUSE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATABOLISM; CLINICAL TRIAL; DATA ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE MARKER; DRUG EFFECT; ENZYME BLOOD LEVEL; FATTY LIVER; HEPATOBILIARY DISEASE; HIGH RISK POPULATION; HUMAN; INCIDENCE; LABORATORY; LIPID BLOOD LEVEL; MEASUREMENT; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK ASSESSMENT;

ALCOHOL DRINKING; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; OXIDATIVE STRESS; RISK FACTORS;

EID: 33748041666     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.04.010     Document Type: Article

References (53)

1. Paolicchi A., Minotti G., Tonarelli P., et al. Gamma-glutamyl transpeptidase-dependent iron reduction and LDL oxidation - a potential mechanism in atherosclerosis. J Invest Med 47 (1999) 151-160
2. Paolicchi A., Emdin M., Ghliozeni E., et al. Human atherosclerotic plaques contain gamma-glutamyl transpeptidase activity. Circulation 109 (2004) 1440
3. Emdin M., Pompella A., and Paolicchi A. Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque. Circulation 112 (2005) 2078-2080
4. Paolicchi A., Emdin M., Passino C., et al. β-Lipoprotein- and LDL-associated serum γ-glutamyltransferase in patients with coronary atherosclerosis. Atherosclerosis 186 (2006) 80-85
5. Wannamethee G., Ebrahim S., and Shaper A.G. Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol 142 (1995) 699-708
6. Ruttmann E., Brant L.J., Concin H., Diem G., Rapp K., and Ulmer H. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 112 (2005) 2130-2137
7. Lieberman M.W., Barrios R., Carter B.Z., et al. γ-Glutamyl transpeptidase. What does the organization and expression of a multipromoter gene tell us about its functions?. Am J Pathol 147 (1995) 1175-1185
8. Whitfield J.B. Gamma glutamyl transferase. Crit Rev Clin Lab Sci 38 (2001) 263-355
9. Goldberg D.M. Structural, functional, and clinical aspects of gamma-glutamyltransferase. Crit Rev Clin Lab Sci 12 (1980) 1-58
10. Nemesanszky E., and Lott J. Gamma-glutamyltransferase and its isoenzymes: progress and problems. Clin Chem 31 (1985) 797-803
11. Sotil E.U., and Jensen D.M. Serum enzymes associated with cholestasis. Clin Liver Dis 8 (2004) 41-54
12. Cabrera-Abreu J.C., and Green A. Gamma-glutamyltransferase: value of its measurement in paediatrics. Ann Clin Biochem 39 Pt. 1 (2002) 22-25
13. Henry J.B. Clinical diagnosis and management by laboratory methods. 20th ed. (2001), W.B. Saunders, Philadelphia
14. Salvaggio A., Periti M., Miano L., et al. Body mass index and liver enzyme activity in serum. Clin Chem 37 (1991) 720-723
15. Nilssen O., Førde O.H., Brenn T., and The Tromsø Study. Distribution and population determinants of gamma-glutamyltransferase. Am J Epidemiol 132 (1990) 318-326
16. Combes B., Shore G.M., Cunningham F.G., et al. Serum gamma-glutamyl transpeptidase activity in viral hepatitis: suppression in pregnancy and by birth control pills. Gastroenterology 72 (1977) 271-274
17. Persijn J.P., and van der Slik W. A new method for the determination of gamma-glutamyltransferase in serum. J Clin Chem Clin Biochem 14 (1976) 421-427
18. Teschke R., Brand A., and Strohmeyer G. Induction of hepatic microsomal gamma-glutamyltransferase activity following chronic alcohol consumption. Biochem Biophys Res Commun 75 (1977) 718-724
19. Cushman P., Jacobson G., Barboriak J.J., and Anderson A.J. Biochemical markers for alcoholism: sensitivity problems. Alcohol Clin Exp Res 8 (1984) 253-257
20. Poikolainen K., Karkkainen P., and Pikkarainen J. Correlations between biological markers and alcohol intake as measured by diary and questionnaire in men. J Stud Alcohol 46 (1985) 383-387
21. Muntwyler J., Hennekens C.H., Buring J.E., and Gaziano J.M. Mortality and light to moderate alcohol consumption after myocardial infarction. Lancet 352 (1998) 1882-1885
22. Dixon A.F., Dixon J.B., and O'Brien P.E. Cardiovascular benefit of light to moderate alcohol consumption. Aust Fam Physician 32 (2003) 649-652
23. Betro M.G., Oon R.C., and Edwards J.B. Gamma-glutamyl transpeptidase and other liver function tests in myocardial infarction and heart failure. Am J Clin Pathol 60 (1973) 679-683
24. Peterson B., Trell E., Kristensson H., Fex G., Yettra M., and Hood B. Comparison of gamma-glutamyltransferase and other health screening tests in average middle-aged males, heavy drinkers and alcohol non-users. Scand J Clin Lab Invest 43 (1983) 141-149
25. Arnesen E., Huseby N.E., Brenn T., and Try K. The Tromsø Heart Study: distribution of, and determinants for, gamma-glutamyltransferase in a free-living population. Scand J Clin Lab Invest 46 (1986) 63-70
26. Nystrom E., Bengtsson C., Lindstedt G., Lapidus L., Lindquist O., and Waldenstrom J. Serum gamma-glutamyltransferase in a Swedish female population. Age-related reference intervals; morbidity and prognosis in cases with raised catalytic concentration. Acta Med Scand 224 (1988) 79-84
27. van Barneveld T., Seidell J.C., Traag N., and Hautvast J.G. Fat distribution and gamma-glutamyl transferase in relation to serum lipids and blood pressure in 38-year old Dutch males. Eur J Clin Nutr 43 (1989) 809-818
28. Yamada Y., Ishizaki M., Kido T., Honda R., Tsuritani I., and Yamaya H. Relationship between serum gamma-glutamyl transpeptidase activity and blood pressure in middle-aged male and female non-drinkers. J Hum Hypertens 4 (1990) 609-614
29. Nilssen O., and Førde O.H. Seven-year longitudinal population study of change in gamma-glutamyltransferase: the Tromsø Study. Am J Epidemiol 139 (1994) 787-792
30. Kim D.J., Noh J.H., Cho N.H., et al. Serum γ-glutamyltransferase within its normal concentration range is related to the presence of diabetes and cardiovascular risk factors. Diabet Med 22 (2005) 1134-1140
31. Brenner H., Rothenbacher D., Arndt V., Schuberth S., Fraisse E., and Fliedner T.M. Distribution, determinants, and prognostic value of gamma-glutamyltransferase for all-cause mortality in a cohort of construction workers from southern Germany. Prev Med 26 (1997) 305-310
32. Lee D.H., Jacobs D.R., Gross M., et al. γ-Glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem 49 (2003) 1358-1366
33. Lee D.H., Ha M.H., Kim K.Y., Jin D.G., and Jacobs D.R. Gamma-glutamyltransferase: an effect modifier in the association between age and hypertension in a 4-year follow-up study. J Hum Hypertens 18 (2004) 803-807
34. Jousilahti P., Rastenyte D., and Tuomilehto J. Serum gamma-glutamyl transferase, self-reported alcohol drinking, and the risk of stroke. Stroke 31 (2000) 1851-1855
35. Bots M.L., Salonen J.T., Elwood P.C., et al. Gamma-glutamyltransferase and risk of stroke: the EUROSTROKE project. J Epidemiol Community Health 56 Suppl. 1 (2002) i25-i29
36. Perry I.J., Wannamethee S.G., and Shaper A.G. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care 21 (1998) 732-737
37. Lee D.H., Ha M.H., Kim J.H., et al. Gamma-glutamyltransferase and diabetes - a 4 year follow-up study. Diabetologia 46 (2003) 359-364
38. Lee D.H., Silventoinen K., Jacobs D.R., Jousilahti P., and Tuomileto J. γ-Glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women. J Clin Endocrinol Metab 89 (2004) 5410-5414
39. Schulze P.C., and Lee R.T. Oxidative stress and atherosclerosis. Curr Atheroscler Rep 7 (2005) 242-248
40. Moriya S., Nagata S., Yokoyama H., et al. Expression of gamma-glutamyl transpeptidase mRNA after depletion of glutathione in rat liver. Alcohol Alcohol Suppl 29 (1994) 107-111
41. Lee D.H., Blomhoff R., and Jacobs D.R. Is serum gamma glutamyltransferase a marker of oxidative stress?. Free Radic Res 38 (2004) 535-539
42. Emdin M., Passino C., Michelassi C., et al. Prognostic value of serum gamma-glutamyl transferase activity after myocardial infarction. Eur Heart J 22 (2001) 1802-1807
43. Huseby N.E. Multiple forms of serum gamma-glutamyltransferase. Association of the enzyme with lipoproteins. Clin Chim Acta 124 (1982) 103-112
44. Gurdol F., Nwose O.M., and Mikhailidis D.P. γ-Glutamyl transferase activity in human platelets: quantification of activity, isoenzyme characterization and potential clinical relevance. Platelets 6 (1995) 200-203
45. Bolodeoku J.A., Ganotakis E.S., Mikhailidis D.P., and Winder A.F. Correlation between serum γ-glutamyl transferase activity and the platelet count. Platelets 8 (1997) 333-335
46. Fukuo Y., Kitami T., Nomoto T., and Terashi A. A lipid lowering drug (bezafibrate) has a favorable effect on liver enzymes (Al-P and gamma-GTP). Nippon Ika Daigaku Zasshi 63 (1996) 424-430
47. Mikhailidis D.P., Ganotakis E.S., Spyropoulos K.A., Jagroop I.A., Byrne D.J., and Winder A.F. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice. Int Angiol 17 (1998) 225-233
48. Papadakis J.A., Ganotakis E.S., Jagroop I.A., Winder A.F., and Mikhailidis D.P. Statin + fibrate combination therapy: fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Int J Cardiol 69 (1999) 237-244
49. Villanova N., Moscatiello S., Ramilli S., et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 42 (2005) 473-480
50. Targher G., Bertolini L., Poli F., et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54 (2005) 3541-3546
51. Tsutsumi M., and Takase S. Effect of fenofibrate on fatty liver in rats treated with alcohol. Alcohol Clin Exp Res 25 Suppl. 6 (2001) 75S-79S
52. Pleiner J., Mittermayer F., Schaller G., et al. Inflammation-induced vasoconstrictor hyporeactivity is caused by oxidative stress. J Am Coll Cardiol 42 (2003) 1656-1662
53. Lee D.H., and Jacobs D.R. Association between serum gamma-glutamyltransferase and C-reactive protein. Atherosclerosis 178 (2005) 327-330